摘要
[目的]探讨动态增强磁共振成像(DCE-MRI)定量DCE参数与胃腺癌T、N分期的相关性。[方法]纳入河南省肿瘤医院2019年1月至2021年9月行DCE-MRI检查的胃腺癌患者88例,采用Spearman秩相关分析评价定量DCE参数K^(trans)、K_(ep)、V_(e)与胃腺癌T、N分期的相关性。对上述差异有统计学意义的参数绘制ROC曲线以明确鉴别胃腺癌T、N分期的最佳诊断参数及诊断效能。[结果]定量DCE参数K^(trans)、K_(ep)、V_(e)与T分期间呈正相关(r=0.597、0.510、0.476,P均<0.001)。ROC分析表明V_(e)是鉴别胃腺癌T分期的最佳参数,其AUC值为0.924,灵敏度和特异度分别为100.0%、83.5%。K^(trans)与N分期间呈正相关(r=0.276,P=0.009)。K^(trans)鉴别N分期的AUC值为0.574,灵敏度和特异度分别为47.8%、76.9%。[结论]定量DCE参数与胃腺癌T、N分期存在一定相关性,可能为从DCE-MRI方面评估胃腺癌的生物学行为、恶性程度及治疗方案的选择等提供了理论依据。
[Objective]To investigate the correlation of dynamic contrast-enhanced magnetic resonance imaging(DCE-MRI)parameters with T and N staging of gastric adenocarcinoma.[Methods]Eighty-eight patients with gastric adenocarcinoma who underwent DCE-MRI examination in Henan Cancer Hospital from January 2019 to September 2021 were enrolled.Spearman rank correlation analysis was used to evaluate the correlation of quantitative DCE parameters K^(trans),K_(ep),V_(e) with T and N staging of gastric adenocarcinoma.ROC analysis were performed for the above parameters with statistically significant differences to determine the best diagnostic parameters and their diagnostic performance for T and N staging of gastric adenocarcinoma.[Results]Quantitative DCE parameters K^(trans),K_(ep),V_(e) were positively correlated with T staging(r=0.597,0.510,0.476,all P<0.001),and ROC analysis showed that V_(e) was the best parameter to diagnose T staging of gastric adenocarcinoma,the AUC value was 0.924,and the sensitivity and specificity were 100.0%and83.5%,respectively.K^(trans) was positively correlated with N staging(r=0.276,P=0.009),and the AUC value of K^(trans) to determine N staging was 0.574,and the sensitivity and specificity were47.8%and 76.9%,respectively.[Conclusion]The quantitative DCE parameters are correlated with T and N staging of gastric adenocarcinoma,indicating that DCE-MRI may be used to evaluate the biological behavior,malignant degree and treatment options of gastric adenocarcinoma.
作者
吴越
闫亮亮
黎海亮
许春苗
窦新民
WU Yue;YAN Liang-liang;LI Hai-liang;XU Chun-miao;DOU Xin-min(Affiliated Cancer Hospital of Zhengzhou University&Henan Cancer Hospital,Zhengzhou 450008,China)
出处
《肿瘤学杂志》
CAS
2022年第4期285-290,共6页
Journal of Chinese Oncology
